AbbVie Inc (ABBV) : Capital Research Global Investors scooped up 2,635,205 additional shares in AbbVie Inc during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of 77,568,659 shares of AbbVie Inc which is valued at $4,388.1 Million.AbbVie Inc makes up approximately 1.52% of Capital Research Global Investors’s portfolio.
Other Hedge Funds, Including , Fil Ltd boosted its stake in ABBV during the Q4 period, The investment management firm added 67,099 additional shares and now holds a total of 844,538 shares of AbbVie Inc which is valued at $47.8 Million. AbbVie Inc makes up approx 0.15% of Fil Ltd’s portfolio.Agran Libbie boosted its stake in ABBV during the Q4 period, The investment management firm added 1,675 additional shares and now holds a total of 44,188 shares of AbbVie Inc which is valued at $2.5 Million. AbbVie Inc makes up approx 0.65% of Agran Libbie’s portfolio.Grisanti Capital Management reduced its stake in ABBV by selling 13,535 shares or 3.35% during the fourth quarter. The Hedge Fund company now holds 391,015 shares of ABBV which is valued at $22.1 Million. AbbVie Inc makes up approx 10.08% of Grisanti Capital Management’s portfolio.Boston Partners reduced its stake in ABBV by selling 2,728,071 shares or 62.16% during the fourth quarter. The Hedge Fund company now holds 1,661,013 shares of ABBV which is valued at $94 Million. AbbVie Inc makes up approx 0.14% of Boston Partners’s portfolio.Intrust Bank Na reduced its stake in ABBV by selling 1,681 shares or 7.14% during the fourth quarter. The Hedge Fund company now holds 21,871 shares of ABBV which is valued at $1.2 Million. AbbVie Inc makes up approx 0.47% of Intrust Bank Na’s portfolio.
On the company’s financial health, AbbVie Inc reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $1.12. The company had revenue of $6400.00 million for the quarter, compared to analysts expectations of $6382.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS.
Investors should note that on Feb 18, 2016, AbbVie Inc announced a cash dividend of $0.5700. The company’s management has announced Apr 13, 2016 as the ex-dividend date and fixed the record date on Apr 15, 2016. The payable date has been fixed on May 16, 2016.
Many Wall Street Analysts have commented on AbbVie Inc. Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016. Shares were Downgraded by Barclays on Dec 1, 2015 to ” Equal Weight” and Lowered the Price Target to $ 72 from a previous price target of $73 .
AbbVie Inc closed down -0.56 points or -0.99% at $56.01 with 66,32,920 shares getting traded on Monday. Post opening the session at $56.52, the shares hit an intraday low of $55.73 and an intraday high of $56.775 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.